ATE410157T1 - Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität - Google Patents
Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivitätInfo
- Publication number
- ATE410157T1 ATE410157T1 AT00954081T AT00954081T ATE410157T1 AT E410157 T1 ATE410157 T1 AT E410157T1 AT 00954081 T AT00954081 T AT 00954081T AT 00954081 T AT00954081 T AT 00954081T AT E410157 T1 ATE410157 T1 AT E410157T1
- Authority
- AT
- Austria
- Prior art keywords
- attention deficit
- hyperactivity
- treatment
- composition containing
- modafinil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14961299P | 1999-08-16 | 1999-08-16 | |
US09/638,353 US6346548B1 (en) | 1999-08-16 | 2000-08-15 | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE410157T1 true ATE410157T1 (de) | 2008-10-15 |
Family
ID=26846889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00954081T ATE410157T1 (de) | 1999-08-16 | 2000-08-16 | Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität |
Country Status (20)
Country | Link |
---|---|
US (3) | US6346548B1 (de) |
EP (1) | EP1253918B1 (de) |
JP (1) | JP5542291B2 (de) |
KR (1) | KR100728080B1 (de) |
CN (1) | CN100450475C (de) |
AT (1) | ATE410157T1 (de) |
AU (1) | AU778360B2 (de) |
BR (1) | BR0013555A (de) |
CA (2) | CA2689735A1 (de) |
CY (1) | CY1109079T1 (de) |
DE (1) | DE60040487D1 (de) |
DK (1) | DK1253918T3 (de) |
ES (1) | ES2313902T3 (de) |
HK (1) | HK1051006A1 (de) |
IL (2) | IL147794A0 (de) |
MX (1) | MXPA02001587A (de) |
NO (1) | NO331307B1 (de) |
NZ (1) | NZ516767A (de) |
PT (1) | PT1253918E (de) |
WO (1) | WO2001012170A2 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
DE20122504U1 (de) * | 2000-07-27 | 2005-12-29 | Teva Pharmaceutical Industries Ltd. | Kristallines und reines Modafinil |
US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
DE60219005T2 (de) * | 2001-05-25 | 2007-12-13 | Cephalon, Inc. | Modafinil umfassende feste pharmazeutische Formulierungen |
EP1401483A1 (de) | 2001-06-11 | 2004-03-31 | Transition Therapeutics Inc. | Kombinationstherapie enthaltend vitamin b12 und therapeutische wirkstoffe zur behandlung von viral-, proliferativen- und entzündlichen erkrankungen |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US6821979B2 (en) * | 2002-03-07 | 2004-11-23 | Blanchette Rockefeller Neurosciences Institute | Synergistic enhancement of cognitive ability |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
US6992219B2 (en) | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
CN101606916B (zh) * | 2002-09-13 | 2011-02-09 | 赛福伦公司 | 莫达非尼片剂及其应用 |
US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
US8153159B2 (en) * | 2003-09-18 | 2012-04-10 | Cephalon, Inc. | Modafinil modified release pharmaceutical compositions |
US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
US20050137264A1 (en) * | 2003-12-22 | 2005-06-23 | Patel Ashish A. | Modafinil compositions |
US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
EP1586560A1 (de) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituierte Arylmethansulfinyl-Derivate |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
WO2006032146A1 (en) * | 2004-09-24 | 2006-03-30 | Centre For Addiction And Mental Health | The use of a modafinil compound for the treatment of problem gambling |
PL1912650T3 (pl) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Zastosowanie flibanseryny w leczeniu otyłości |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
CA2641917A1 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
JP2009536176A (ja) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 |
US20090312242A1 (en) * | 2006-06-30 | 2009-12-17 | Ramiro Castro | Flibanserin for the treatment of urinary incontinence and related diseases |
JP2009543803A (ja) * | 2006-07-12 | 2009-12-10 | エラン・ファルマ・インターナショナル・リミテッド | モダフィニルのナノ粒子製剤 |
EP2043648A1 (de) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Verwendung von flibanserin zur behandlung von sexualstörungen bei frauen |
FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
AR062320A1 (es) | 2006-08-14 | 2008-10-29 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
CN104721168A (zh) * | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
US20100010092A1 (en) * | 2006-12-19 | 2010-01-14 | Arless Ltd. | Use of modafinil to treat restless leg syndrome |
US8304601B2 (en) * | 2007-01-23 | 2012-11-06 | Keiko Fujikawa | Mouse model for eye disease |
US9289403B2 (en) * | 2007-03-09 | 2016-03-22 | The Board of Trustees of the University of Arizona | Use of modafinil to treat spasticity |
UY31335A1 (es) * | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
US20090082462A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched armodafinil |
EP2238973A1 (de) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilisierte Präparate von Proteasominhibitoren |
FR2970711B1 (fr) | 2011-01-20 | 2016-03-04 | Hopitaux Paris Assist Publique | La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
KR102150417B1 (ko) * | 2018-08-29 | 2020-09-01 | 경북대학교 산학협력단 | 복외측전시각영역 내 성상세포의 광유전학적 자극을 통한 수면 유도 동물 모델 및 이를 이용한 수면 제어제의 스크리닝 방법 |
GB201821066D0 (en) * | 2018-12-21 | 2019-02-06 | Univ Oxford Innovation Ltd | Sleep modulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
FR2593809B1 (fr) | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
FR2707637B1 (fr) | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
DE60019904T2 (de) * | 1999-02-24 | 2006-05-04 | University Of Cincinnati, Cincinnati | Verwendung von sulfamatderivaten zur behandlung von impulskontrollerkrankungen |
-
2000
- 2000-08-15 US US09/638,353 patent/US6346548B1/en not_active Expired - Lifetime
- 2000-08-16 NZ NZ516767A patent/NZ516767A/en not_active IP Right Cessation
- 2000-08-16 ES ES00954081T patent/ES2313902T3/es not_active Expired - Lifetime
- 2000-08-16 CA CA002689735A patent/CA2689735A1/en not_active Abandoned
- 2000-08-16 DE DE60040487T patent/DE60040487D1/de not_active Expired - Lifetime
- 2000-08-16 CN CNB008111820A patent/CN100450475C/zh not_active Expired - Fee Related
- 2000-08-16 AU AU66424/00A patent/AU778360B2/en not_active Ceased
- 2000-08-16 MX MXPA02001587A patent/MXPA02001587A/es active IP Right Grant
- 2000-08-16 JP JP2001516516A patent/JP5542291B2/ja not_active Expired - Lifetime
- 2000-08-16 DK DK00954081T patent/DK1253918T3/da active
- 2000-08-16 CA CA2380673A patent/CA2380673C/en not_active Expired - Fee Related
- 2000-08-16 WO PCT/US2000/022338 patent/WO2001012170A2/en active IP Right Grant
- 2000-08-16 BR BRPI0013555-0A patent/BR0013555A/pt not_active Application Discontinuation
- 2000-08-16 IL IL14779400A patent/IL147794A0/xx active IP Right Grant
- 2000-08-16 PT PT00954081T patent/PT1253918E/pt unknown
- 2000-08-16 AT AT00954081T patent/ATE410157T1/de active
- 2000-08-16 EP EP00954081A patent/EP1253918B1/de not_active Expired - Lifetime
- 2000-08-16 KR KR1020027001958A patent/KR100728080B1/ko not_active IP Right Cessation
-
2001
- 2001-12-20 US US10/029,306 patent/US6488164B2/en not_active Expired - Lifetime
-
2002
- 2002-01-23 IL IL147794A patent/IL147794A/en not_active IP Right Cessation
- 2002-02-15 NO NO20020772A patent/NO331307B1/no not_active IP Right Cessation
- 2002-10-30 US US10/283,573 patent/US7087647B2/en not_active Expired - Fee Related
-
2003
- 2003-05-06 HK HK03103227.6A patent/HK1051006A1/xx not_active IP Right Cessation
-
2008
- 2008-12-22 CY CY20081101486T patent/CY1109079T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE410157T1 (de) | Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität | |
DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
DE69034149D1 (de) | Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen | |
ATE207351T1 (de) | Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden | |
DE60333857D1 (de) | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
NZ502527A (en) | Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease | |
EA200001258A1 (ru) | Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой | |
DE69813839D1 (de) | Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz | |
ATE497809T1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
DE69421778D1 (de) | Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut | |
DE69826023D1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome | |
DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
DE69829202D1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
EA199800152A1 (ru) | Лечение синдрома дефицита внимания/гиперактивности | |
MY126607A (en) | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue | |
ATE357914T1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
NO984189L (no) | FremgangsmÕte for behandling av bipolar forstyrrelse | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE249832T1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
ATE238067T1 (de) | Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe | |
ATE273712T1 (de) | Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer | |
DE60224078D1 (de) | Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind. | |
TH124101B (th) | องค์ประกอบที่ประกอบด้วยโมแดฟินิลสำหรับการรักษาแอทเทนชัน เดฟิซิท ไฮเปอร์แอกทิวิตี้ ดิสออร์เดอร์และความล้าเหตุมัลติเพิลสคลีโรซีส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1253918 Country of ref document: EP |